Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study

Abstract

Objective To prospectively evaluate predictors of incomplete recovery after the first attacks in a cohort of patients with clinically isolated syndrome or relapsing—remitting multiple sclerosis.

Methods Seventy-two consecutive patients recruited from January 2001 to December 2003, evaluated every six months or at any relapse up to 31 July 2005. Relapse intervals were calculated from the date of onset, nadir, onset of improvement and maximum improvement. Predictive factors analysed were relapse-related (age at relapse onset, season and severity of the relapse, type of symptoms, speed of onset, plateau and total duration, number of affected Functional systems, preceding infections) and individual-related (gender, age at first attack, season of birth and first attack, characteristics of first brain MRI and cerebrospinal fluid oligoclonal bands, Link Index, IgG).

Results We counted 209 attacks: 44 (21%) left mild sequelae, and 27 (13%) severe. The highest probability of sequelae was associated with sphincteric symptoms (9/20; 45%), followed by sensitive (38/113; 34%), motor (20/84; 24%), visual (13/61; 21%), cerebellar (4/24; 17%), brainstem (5/44; 11%) and others (0/6) ( P 0.005). Four variables were still relevant to predict sequelae after multivariate analysis: mild, moderate or severe relapses versus very mild (Odds ratio = 17.2, 95% confidence limits = 2.2—136.4), intermediate or long relapses versus short (3.2, 1.5—6.9), age ≥ 30 at relapse onset (2.9, 1.5—5.7) and bi-polysymptomatic versus monosymptomatic (2.2, 1.1—4.3).

Conclusions Factors predicting incomplete recovery are more closely linked to the characteristics of the single relapse (extension and duration of tissue damage) than to the patient's genetic and environmental background. Multiple Sclerosis 2008; 14: 485—493. http://msj.sagepub.com

Keywords

multiple sclerosis prognosis recovery relapse

References

Confavreux C. , Vukusic S. , Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process . Brain 2003; 126: 770-82.

Weinshenker BG , Rice GP , Noseworthy JH , Carriere W. , Baskerville J. , Ebers GC The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials . Brain 1991 ; 114: 1057-67.

Miller D. , Barkhof F. , Montalban X. , Thompson A. , Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis . Lancet Neurol 2005; 4: 281-8.

Buljevac D. , Flach HZ , Hop WC , Hijdra D. , Laman JD , Savelkoul HF et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations . Brain 2002 ; 125: 952-60.

Lublin FD , Baier M. , Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis . Neurology 2003; 61: 1528-32.

West T. , Wyatt M. , High A. , Bostrom A. , Waubant E.

Are initial demyelinating event recovery and time to second event under differential control?

Neurology 2006 ; 67: 809-13.

Eriksson M. , Andersen O. , Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis . Multiple Sclerosis 2003; 9: 260-74.

Amato MP , Ponziani G. , Bartolozzi ML , Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials . J Neurol Sci 1999; 168: 96-106.

Trojano M. , Avolio C. , Manzari C. , Calo A. , De Robertis F , Serio G. et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events . J Neurol Neurosurg Psychiatry 1995; 58: 300-6.

10.

Liu C. , Blumhardt LD

Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better?

Multiple Sclerosis 1999; 5: 22-8.

11.

Hickman SJ , Toosy AT , Miszkiel KA , Jones SJ , Altmann DR , MacManus DG et al. Visual recovery following acute optic neuritis-a clinical, electrophysiological and magnetic resonance imaging study . J Neurol 2004; 251: 996-1005.

12.

O'Riordan JI , Thompson AJ , Kingsley DP , Pattison C. , Hirsch NP , Howard RS et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up . Brain 1998 ; 121: 495-503.

13.

McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis . Ann Neurol 2001; 50: 121-7.

14.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-52.

15.

Schumacker GA , Beebe G. , Kibler RF , Kurland LT , Kurtzke JF , Mcdowell F. et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis . Ann N Y Acad Sci 1965; 122: 552-68.

16.

Confavreux C. , Compston DA , Hommes OR , McDonald WI , Thompson AJ EDMUS, a European database for multiple sclerosis . J Neurol Neurosurg Psychiatry 1992; 55: 671-6.

17.

Landis JR , Koch GG The measurement of observer agreement for categorical data . Biometrics 1977; 33: 159-74.

18.

Korteweg T. , Tintoré M. , Uitdehaag B. , Rovira A. , Frederiksen J. , Miller D. et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study . Lancet Neurol 2006; 5: 221-7.

19.

SAS Institute Inc. , SUGI supplemental library user's guide. Version 8 edition. Cary, NC: SAS Institute, 1999- 2001.

20.

Cornfield J. A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix . J Natl Cancer Inst 1951; 11: 1269-75.

21.

Butzkueven H. , Mechati S. , Hoffmann M. , Arruda WO , Bacile E. , Boz C. et al. Is the current trial definition of confirmed disability progression in multiple sclerosis an accurate measure of permanent disease progression? Multiple Sclerosis 2006; 12: S1-S228.

22.

Noseworthy JH , Vandervoort MK , Wong CJ , Ebers GC Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group . Neurology . 1990; 40: 971-5.

23.

Beck RW , Cleary PA , Backlund JC The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial . Ophthalmology 1994 ; 101: 1771-8.

24.

Smith KJ , McDonald WI The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease . Philos Trans R Soc Lond B Biol Sci 1999; 354: 1649-73.

25.

Rudick RA , Lee JC , Simon J. , Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study . Ann Neurol 2006; 60: 236-42.

26.

Bergamaschi R. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision . Expert Rev Neurother 2006; 6: 357-64.

27.

Confavreux C. , Vukusic S. , Moreau T. , Adeleine P. Relapses and progression of disability in multiple sclerosis . N Engl J Med 2000; 343: 1430-8.

28.

Frohman EM , Filippi M. , Stuve O. , Waxman SG , Corboy J. , Phillips JT et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions . Arch Neurol 2005; 62: 1345-56.

29.

Kremenchutzky M. , Rice GP , Baskerville J. , Wingerchuk DM , Ebers GC The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease . Brain 2006 ; 129: 584-94.

30.

Filippini G. , Brusaferri F. , Sibley WA , Citterio A. , Ciucci G. , Midgard R. et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis . Cochrane Database Syst Rev 2000; 4: CD001331.

31.

Sharrack B. , Hughes RA , Soudain S. , Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis . Brain 1999 ; 122: 141-59.

32.

Patzold T. , Schwengelbeck M. , Ossege LM , Malin JO , Sindern E. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis . Acta Neurol Scand 2002; 105: 164-8.

33.

Foong J. , Rozewicz L. , Quaghebeur G. , Thompson AJ , Miller DH , Ron MA Neuropsychological deficits in multiple sclerosis after acute relapse . J Neurol Neurosurg Psychiatry 1998; 64: 529-32.

34.

Lucchinetti C. , Bruck W. , Parisi J. , Scheithauer B. , Rodriguez M. , Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination . Ann Neurol 2000; 47: 707-17.